Mirum Pharmaceuticals Files 8-K Report
Ticker: MIRM · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1759425
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Mirum Pharma filed an 8-K for 'Other Events' - keep an eye out for updates.
AI Summary
On June 17, 2024, Mirum Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specific details regarding transactions, agreements, or material events are detailed in the provided text, but it serves as a notification to the SEC.
Why It Matters
This filing serves as an official notification to the SEC regarding "Other Events" at Mirum Pharmaceuticals, Inc., which could signal upcoming or recently occurred material changes for investors.
Risk Assessment
Risk Level: low — The filing itself is a procedural notification and does not contain specific negative or positive financial or operational information.
Key Players & Entities
- Mirum Pharmaceuticals, Inc. (company) — Registrant
- June 17, 2024 (date) — Date of Report
- 001-38981 (company) — SEC File Number
- 83-1281555 (company) — IRS Employer Identification No.
- 989 East Hillsdale Boulevard Suite 300 Foster City, California 94404 (company) — Principal Executive Offices Address
- (650) 667-4085 (company) — Registrant's telephone number
FAQ
What specific event triggered the filing of this 8-K report by Mirum Pharmaceuticals, Inc.?
The filing indicates the report is for 'Other Events' but does not specify the exact event in the provided text.
When was this 8-K report filed with the SEC?
The report was filed on June 17, 2024.
What is the principal executive office address for Mirum Pharmaceuticals, Inc.?
The principal executive office is located at 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404.
What is the SEC file number for Mirum Pharmaceuticals, Inc.?
The SEC file number is 001-38981.
Does this filing provide details on any new agreements or transactions?
The provided text of the 8-K filing does not detail any specific agreements or transactions, only that it is for 'Other Events'.
Filing Stats: 809 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2024-06-17 08:03:33
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MIRM Nasdaq Global Market
Filing Documents
- d853346d8k.htm (8-K) — 26KB
- 0001193125-24-162056.txt ( ) — 149KB
- mirm-20240617.xsd (EX-101.SCH) — 3KB
- mirm-20240617_lab.xml (EX-101.LAB) — 18KB
- mirm-20240617_pre.xml (EX-101.PRE) — 11KB
- d853346d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding the anticipated continuation of the VANTAGE and VISTAS clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with research and development of pharmaceutical product candidates, as well as risks and uncertainties inherent in the Company's business, including those described in the Company's other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: June 17, 2024 By: /s/ Christopher Peetz Christopher Peetz Chief Executive Officer